The Breast Cancer Research Scandal: Addressing the Issues


The three claims put forward by Dr. Roger Poisson to rationalize his enrollment of ineligible subjects in clinical trials do not justify research fraud. None the less, certain lessons for the conduct of clinical research can be learned from the affair: experimental therapies should be made available to technically ineligible subjects when no effective therapy exists for their disease; further research must investigate the possible benefits of clinical-trial participation; broadly based, pragmatic trials must be regarded as the ideal model; and each eligibility criterion in a clinical-trial protocol should be justified.



    Upload a copy of this work     Papers currently archived: 89,703

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

  • Only published works are available at libraries.

Similar books and articles

The Research Misconception.Maurie Markman - 2004 - International Journal of Applied Philosophy 18 (2):241-252.
What the doctor didn't say: the hidden truth about medical research.Jerry Menikoff - 2006 - New York: Oxford University Press. Edited by Edward P. Richards.
Informed consent in emergency research: A contradiction in terms.Malcolm G. Booth - 2007 - Science and Engineering Ethics 13 (3):351-359.


Added to PP

10 (#1,015,470)

6 months
1 (#1,016,089)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Charles Weijer
University of Western Ontario

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references